CClinicalTrials.gg
CompletedNCT00001177Updated Aug 18, 2026

Study of Premenstrual Syndrome and Premenstrual Dysphoria

An observational study in Mood Disorder, sponsored by National Institute of Mental Health (NIMH). Completed at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by National Institute of Mental Health (NIMH) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,569
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The purpose of this study is to identify and describe the symptoms of premenstrual syndrome (PMS).

Women who experience PMS symptoms will complete clinical interviews, self-rating scales, and evaluations of mood and endocrine function. A subgroup of women with severe PMS (Premenstrual Dysphoric Disorder or PMDD) will be offered additional research studies that focus on: 1) identifying the endocrine changes that may be responsible for changes in mood and behavior during the premenstrual period, 2) evaluating treatments for PMS symptoms, and/or 3) identifying genetic factors in women with and without PMS. Women with recurrent brief depression will also be recruited to serve as a comparison group.

Read the detailed description

The purpose of this screening protocol is to identify a population of women who experience menstrually-related mood or behavior difficulties and to describe the symptoms in this group and their relationship to the menses. This will be accomplished by means of clinical interviews, self-rating scales, and periodic evaluation of mood and endocrine function. We further wish to identify and recruit a subgroup of women with menstrually-related mood disorder for participation in specific neuroendocrine/neurophysiologic studies (companion protocols) in an attempt to identify endocrinologic or physiologic measures that might: 1) be associated with the discrete changes in mood and behavior; 2) distinguish this group from a group of age-matched controls; 3) allow for further subgroup definition on the basis of predicted response to pharmacological intervention. Finally, we wish to identify a group of women with recurrent brief depression, who will serve as an additional control group for the patients with menstrual cycle-related mood disorders.

02

Conditions studied

  • Mood Disorder

Keywords

  • Cognition
  • Neuroendocrine
  • PMS Premenstrual Syndrome
  • MRMD Menstrually Related Mood Disorder
  • Menstrual
03

In context

Mood Disorders

584 studies on the registry are indexed under Mood Disorders; 117 are open to participants now.

This study's enrollment of 1,569 is above the median of 180 across 145 observational studies indexed under Mood Disorders.

Browse Mood Disorders studies →

Lead sponsor

National Institute of Mental Health (NIMH) is the lead sponsor of 359 studies on the registry; 46 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 24 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll up to 700 females with menstrually-related mood or behavioral difficulties and 900 healthy volunteers.

Inclusion criteria

The subjects of this study will be women who meet the following criteria:

  • history within the last two years of at least six months with menstrually-related mood or behavioral disturbances of at least moderate severity - that is, disturbances that are distinct in appearance and associated with a notable degree of subjective distress;
  • a 30% increase in mean negative mood ratings (relative to the range of the scale employed) in the premenstrual week compared with the week following the end of menses in at least two of three cycles;
  • age 18 to 50;
  • not pregnant and in good medical health;
  • regular menses.

For subjects with recurrent brief depression:

  • dysphoric mood or loss of interest or pleasure;
  • duration less than two weeks;
  • four of the following symptoms: poor appetite or significant weight loss (when not dieting) or increased appetite or significant weight gain; insomnia or hypersomnia; psychomotor agitation or retardation; loss of interest or pleasure in usual activities, or decrease in sexual drive; loss of energy; fatigue; feelings of worthlessness, self-reproach, or excessive or inappropriate guilt; diminished ability to think or concentrate, slowed thinking, or indecisiveness;
  • impairment in usual occupational activities;
  • at least one-two episodes per month over one year.

Age-matched women without mood and behavioral disorders will be recruited.

Exclusion criteria

EXCLUSION CRITERIA for all study participants:

  • Subjects should have no general medical illness that is primary (i.e., appears to be causing the mood disorder);
  • Current antidepressant therapy (since this is a screening protocol for subsequent treatment and physiologic evaluation studies in which participants must be untreated). Antidepressants will not be withheld from participants who need or want them;
  • Current alcohol or substance use or dependence (excluding nicotine) of sufficient magnitude to require independent, concurrent treatment intervention (e.g., antabuse or opiate treatment, but not including self-help groups).
  • Pregnant or lactating women
  • Subjects who are unable to provide informed consent
  • NIMH employees/staff and their immediate family members will be excluded from the study per NIMH policy.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,569 participants (actual)

Groups and cohorts

  • healthy volunteers

    healthy females

  • patients

    females with menstrually-related mood or behavioral difficulties

06

What researchers measure

Primary outcomes

  1. Standardized cross-sectional rating scales (Beck Depression Inventory, Hamilton Depression and Anxiety Scales, and the Rating Scale for Premenstrual Tension Syndrome), symptom rating scales completed daily, and plasma hormone measures (including...

    Standardized cross-sectional rating scales (Beck Depression Inventory, Hamilton Depression and Anxiety Scales, and the Rating Scale for Premenstrual Tension Syndrome), symptom rating scales completed daily, and plasma hormone measures (including neurosteroid levels).

    Time frame: Ongoing

Secondary outcomes

  1. Plasma ACTH and cortisol response, selected variants in genomic profile (e.g., SNPs) and genome/exome sequencing, metabolomic profiles, and the results of the SCID interviews (e.g. past history of postpartum depression).

    Plasma ACTH and cortisol response, selected variants in genomic profile (e.g., SNPs) and genome/exome sequencing, metabolomic profiles, and the results of the SCID interviews (e.g. past history of postpartum depression).

    Time frame: ongoing

07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

References and documents

Publications

  • Rubinow DR. The premenstrual syndrome. New views. JAMA. 1992 Oct 14;268(14):1908-12. No abstract available. PubMed 1404717 ↗
  • Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998 Jan 22;338(4):209-16. doi: 10.1056/NEJM199801223380401. PubMed 9435325 ↗
  • Bancroft J. The premenstrual syndrome--a reappraisal of the concept and the evidence. Psychol Med. 1993;Suppl 24:1-47. doi: 10.1017/s0264180100001272. PubMed 7906420 ↗
  • Zou CX, Guerrieri GM, Martinez PE, Li X, Ben Dor R, Bovell RTM, Naredo Rojas JM, McCluggage P, Kress N, Neiman LK, Rubinow DR, Schmidt PJ. Cortisol and ACTH response to Dex/CRH testing and 24-hour urine free cortisol levels in women with and without premenstrual dysphoric disorder. Psychoneuroendocrinology. 2025 Feb;172:107250. doi: 10.1016/j.psyneuen.2024.107250. Epub 2024 Nov 30. PubMed 39644712 ↗

Individual participant data

Plan to share: Yes — Data will be shared with dbGaP, BTRIS and NIMH Data Archive as determined by the Principal Investigator.

Supporting information: Study protocol, Sap, Icf, Csr

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00001177
Lead sponsor
National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Nov 4, 1999
Start date
Mar 9, 1984
Last update
Aug 18, 2026

Study contacts

Peter J Schmidt, M.D.
principal investigator · National Institute of Mental Health (NIMH)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion